HLN
Haleon Plc
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · GB
$9.28
−0.85%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -4.3%
- EBITDA
- -6.6%
- EPS
- -6.2%
Three-year CAGR
- Revenue
- +0.5%
- EBITDA
- +9.7%
- EBIT
- +9.7%
- Net income
- +15.4%
- EPS
- +14.5%
- Free cash flow
- +4.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026